🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

18,99 USD

Máx. histórico

178,74

2143 días

Split 1:6 del 12/07/2012

Caída desde máximo

-89,38%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+2,43%

Cierre anterior

18,54

Rango de hoy

18,52 – 19,26

Volumen hoy

1.328.200

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 1 día
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
15/04/2002 45,90 47,10 45,60 46,50 -0,51% 3,27% 7.850
12/04/2002 47,40 47,40 45,24 46,74 +0,91% 4,56% 22.683
11/04/2002 43,80 47,64 43,56 46,32 +5,75% 9,32% 33.950
10/04/2002 42,42 43,80 42,30 43,80 +2,82% 3,54% 10.667
09/04/2002 43,80 44,94 42,60 42,60 -0,70% 5,34% 25.600
08/04/2002 40,80 43,20 40,20 42,90 +2,44% 7,35% 23.100
05/04/2002 45,54 45,60 41,10 41,88 -7,55% 9,88% 35.833
04/04/2002 46,20 47,10 45,30 45,30 -1,82% 3,90% 39.250
03/04/2002 45,30 46,20 44,70 46,14 +2,53% 3,31% 33.900
02/04/2002 47,46 48,00 45,00 45,00 -5,66% 6,32% 33.300
01/04/2002 47,70 49,50 46,50 47,70 -2,09% 6,29% 24.133
28/03/2002 49,50 50,40 48,72 48,72 -1,58% 3,39% 32.367
27/03/2002 48,42 50,10 48,00 49,50 +2,61% 4,34% 59.117
26/03/2002 51,12 53,10 47,10 48,24 -3,83% 11,74% 102.600
25/03/2002 54,30 54,30 48,78 50,16 -6,07% 10,17% 43.933
22/03/2002 55,80 56,10 51,90 53,40 -3,78% 7,53% 79.400
21/03/2002 58,80 59,70 55,50 55,50 -4,74% 7,14% 52.100
20/03/2002 60,00 60,30 58,20 58,26 -3,38% 3,50% 20.917
19/03/2002 64,50 64,50 59,94 60,30 -5,63% 7,07% 30.367
18/03/2002 64,80 65,94 63,90 63,90 -3,18% 3,15% 27.700
15/03/2002 66,00 66,06 63,60 66,00 +0,09% 3,73% 28.967
14/03/2002 65,52 68,94 65,10 65,94 -0,99% 5,86% 30.183
13/03/2002 62,94 66,96 62,40 66,60 +5,31% 7,24% 36.683
12/03/2002 59,40 63,24 59,34 63,24 +3,94% 6,57% 20.167
11/03/2002 61,26 61,26 60,00 60,84 -0,29% 2,06% 16.150
08/03/2002 60,12 62,88 60,00 61,02 +1,80% 4,79% 28.300
07/03/2002 60,84 61,50 58,80 59,94 -1,09% 4,44% 9.100
06/03/2002 57,60 60,90 57,12 60,60 +5,87% 6,56% 21.500
05/03/2002 62,16 62,16 55,80 57,24 -6,47% 10,23% 20.733
04/03/2002 59,40 62,82 58,62 61,20 +3,13% 7,07% 27.433